Strategies to decrease taxanes toxicities in the adjuvant treatment of early breast cancer

Keyphrases

• Early Breast Cancer 100%
• Adjuvant Therapy 100%
• Taxanes 100%
• Anthracyclines 33%
• Tumor 8%
• Breast Cancer Treatment 8%
• Response Rate 8%
• Overall Survival 8%
• Cross-resistance 8%
• Highly Active 8%
• Breast Cancer Recurrence 8%
• Early Phase Clinical Trials 8%
• Molecular Markers 8%
• Disease-free 8%
• Randomized Clinical Trial 8%
• Time to Progression 8%
• Survival Benefit 8%
• Cytotoxic Agents 8%
• Concurrent Use 8%
• Therapeutic Index 8%
• Hematotoxicity 8%
• Safety Issues 8%
• Growth Factor Support 8%
• Progression Disease 8%
• Tubulin-targeting Agents 8%

Nursing and Health Professions

• Breast Cancer 100%
• Adjuvant Therapy 100%
• Anthracycline 66%
• Neoplasm 16%
• Overall Survival 16%
• Growth Factor 16%
• Disease Exacerbation 16%
• Molecular Marker 16%
• Cytotoxic Agent 16%
• Tubulin 16%
• Therapeutic Window 16%
• Metastatic Breast Cancer 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Breast Cancer 100%
• Taxane 100%
• Anthracycline 33%
• Clinical Trial 8%
• Neoplasm 8%
• Randomized Clinical Trial 8%
• Overall Survival 8%
• Growth Factor 8%
• Therapeutic Window 8%
• Tubulin 8%
• Metastatic Breast Cancer 8%
• Molecular Marker 8%
• Disease Exacerbation 8%
• Cytotoxic Agent 8%
• Cross-Resistance 8%